Efficacy and moderators of prevention and treatment of delirium with melatonin receptor agonists: A systematic review and meta-analysis of randomized controlled trials

Gen Hosp Psychiatry. 2023 Nov-Dec:85:71-79. doi: 10.1016/j.genhosppsych.2023.08.011. Epub 2023 Sep 1.

Abstract

Objective: Delirium is a complex and heterogeneous condition that significantly affects patient outcome. This study aimed to conduct a systematic review and meta-analysis to investigate the effects of melatonin and melatonin receptor agonists (MRAs) on delirium prevention and treatment.

Method: Randomized controlled studies, using MRAs as an intervention and placebo as a control were included. We conducted meta-analyses with random-effects model and trial sequential analysis.

Results: A total of 33 studies involving 4850 participants were included. The meta-analysis revealed a significant preventive effect of MRAs on delirium (risk ratio = 0.65, p < 0.01), while no significant therapeutic effect was observed. Additionally, MRAs were associated with a significant reduction in mortality rate (risk ratio = 0.90, p = 0.02) in delirium prevention studies. Furthermore, subgroup analyses revealed that assessment scales and the frequency of delirium detection may be significant moderators of the delirium-preventive efficacy of MRAs.

Conclusion: This study provides evidence of the potential effects of MRAs in preventing delirium and reducing mortality. Further research is required to elucidate the therapeutic potential of MRAs for delirium and identify specific patient populations that may benefit from this agent.

Keywords: Delirium; Melatonin; Melatonin receptor agonists; Prevention; Treatment.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Delirium* / drug therapy
  • Delirium* / prevention & control
  • Humans
  • Hypnotics and Sedatives / therapeutic use
  • Melatonin* / pharmacology
  • Melatonin* / therapeutic use
  • Randomized Controlled Trials as Topic
  • Receptors, Melatonin / therapeutic use

Substances

  • Receptors, Melatonin
  • Hypnotics and Sedatives
  • Melatonin